Vaccine/Sample
stringclasses 7
values | Dose
stringclasses 19
values | Geography Type
stringclasses 2
values | Geography
stringclasses 79
values | Survey Year
stringclasses 19
values | Dimension Type
stringclasses 6
values | Dimension
stringclasses 16
values | Estimate (%)
float64 0.4
100
⌀ | 95% CI (%)
stringlengths 10
13
⌀ | Sample Size
float64 30
91.7k
⌀ |
|---|---|---|---|---|---|---|---|---|---|
Tetanus | ≥1 Dose Tdap | States/Local Areas | New York | 2021 | Age | 13-17 Years | 87.3 | 83.4 to 90.4 | 581 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | New York | 2020 | Age | 13-17 Years | 93 | 90.2 to 95.1 | 729 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2017 | Age | 13-17 Years | 89.3 | 85.9 to 91.9 | 651 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | New York | 2019 | Age | 13-17 Years | 93.4 | 90.5 to 95.4 | 498 |
≥2 Doses MMR | null | States/Local Areas | New York | 2016 | Age | 13-17 Years | 92.9 | 90.2 to 94.9 | 655 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | New York | 2016 | Age | 13-17 Years | 91.1 | 88.2 to 93.4 | 655 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | New York | 2018 | Age | 13-17 Years | 91.7 | 88.7 to 94.0 | 535 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | New York | 2017 | Age | 13-17 Years | 92.9 | 90.3 to 94.8 | 651 |
≥2 Doses MMR | null | States/Local Areas | New York | 2013 | Age | 13-17 Years | 93.3 | 90.3 to 95.4 | 710 |
≥2 Doses MMR | null | States/Local Areas | New York | 2012 | Age | 13-17 Years | 93.8 | 90.6 to 96.0 | 627 |
≥2 Doses MMR | null | States/Local Areas | New York | 2015 | Age | 13-17 Years | 94.6 | 92.6 to 96.1 | 665 |
≥2 Doses MMR | null | States/Local Areas | New York | 2014 | Age | 13-17 Years | 91.6 | 88.2 to 94.1 | 594 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2013 | Age | 13-17 Years | 83.3 | 79.7 to 86.4 | 710 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2014 | Age | 13-17 Years | 79.6 | 75.1 to 83.5 | 594 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2015 | Age | 13-17 Years | 86.2 | 82.9 to 89.0 | 665 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2016 | Age | 13-17 Years | 89.2 | 86.0 to 91.8 | 655 |
HPV | ≥3 Doses, Males and Females | States/Local Areas | New York | 2011 | Age | 13-17 Years | 17.4 | 14.6 to 20.5 | 840 |
HPV | ≥3 Doses, Males and Females | States/Local Areas | New York | 2012 | Age | 13-17 Years | 22.2 | 18.1 to 26.9 | 627 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2022 | Age | 13-15 Years | 96 | 93.3 to 97.7 | 320 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2012 | Age | 13-17 Years | 78.5 | 74.1 to 82.3 | 627 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2010 | Age | 13-17 Years | 71.2 | 66.5 to 75.4 | 701 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2011 | Age | 13-17 Years | 74.9 | 70.9 to 78.5 | 840 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2008 | Age | 13-17 Years | 56 | 51.1 to 60.8 | 600 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2009 | Age | 13-17 Years | 62.9 | 57.7 to 67.8 | 539 |
≥1 Dose MenACWY | null | States/Local Areas | New York | 2018-2022 | Overall | Overall | 94.8 | 93.7 to 95.7 | 2,879 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | New York | 2018-2022 | Overall | Overall | 91.2 | 89.8 to 92.4 | 2,879 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2018 | Age | 13-17 Years | 12.5 | 8.3 to 18.4 | 261 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2016 | Age | 13-17 Years | 13.4 | 9.6 to 18.4 | 291 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2015 | Age | 13-17 Years | 13.7 | 10.0 to 18.6 | 313 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2009 | Age | 13-17 Years | 51.1 | 43.5 to 58.7 | 269 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2017 | Age | 13-17 Years | 10 | 6.8 to 14.4 | 281 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2008 | Age | 13-17 Years | 50.1 | 42.9 to 57.2 | 293 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2019 | Age | 13-17 Years | 10.3 | 6.8 to 15.2 | 257 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2020 | Age | 13-17 Years | 6.7 | 4.2 to 10.5 | 381 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2021 | Age | 13-17 Years | 7.8 | 4.6 to 13.0 | 297 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2012 | Age | 13-17 Years | 23.5 | 18.6 to 29.2 | 312 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2013 | Age | 13-17 Years | 20.5 | 15.6 to 26.4 | 300 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2011 | Age | 13-17 Years | 27.2 | 22.7 to 32.1 | 435 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2010 | Age | 13-17 Years | 31.8 | 26.6 to 37.6 | 388 |
HPV | Up-to-Date, Females | States/Local Areas | NY-City of New York | 2019 | Age | 13-15 Years | 60.9 | 47.6 to 72.7 | 84 |
HPV | Up-to-Date, Females | States/Local Areas | NY-City of New York | 2020 | Age | 13-15 Years | 72.1 | 60.0 to 81.6 | 108 |
Varicella | History of disease | States/Local Areas | NY-City of New York | 2014 | Age | 13-17 Years | 22.5 | 16.9 to 29.3 | 288 |
HPV | Up-to-Date, Females | States/Local Areas | NY-City of New York | 2018 | Age | 13-15 Years | 48.7 | 34.7 to 62.8 | 71 |
Varicella | History of disease | States/Local Areas | New Jersey | 2009 | Age | 13-17 Years | 46.3 | 40.6 to 52.0 | 427 |
Varicella | History of disease | States/Local Areas | New Jersey | 2008 | Age | 13-17 Years | 53.1 | 46.9 to 59.3 | 390 |
Varicella | History of disease | States/Local Areas | New Jersey | 2010 | Age | 13-17 Years | 44.7 | 38.2 to 51.4 | 399 |
Varicella | History of disease | States/Local Areas | New Jersey | 2011 | Age | 13-17 Years | 32.8 | 27.6 to 38.4 | 432 |
Varicella | History of disease | States/Local Areas | New Jersey | 2013 | Age | 13-17 Years | 20.5 | 15.4 to 26.7 | 322 |
Varicella | History of disease | States/Local Areas | New Jersey | 2012 | Age | 13-17 Years | 25.1 | 19.6 to 31.4 | 330 |
Varicella | History of disease | States/Local Areas | New Jersey | 2014 | Age | 13-17 Years | 16.8 | 12.2 to 22.8 | 328 |
Varicella | History of disease | States/Local Areas | New Jersey | 2015 | Age | 13-17 Years | 15.7 | 11.6 to 20.9 | 364 |
Varicella | History of disease | States/Local Areas | New Jersey | 2016 | Age | 13-17 Years | 10.3 | 7.4 to 14.2 | 422 |
Varicella | History of disease | States/Local Areas | New Jersey | 2018 | Age | 13-17 Years | 13.8 | 9.7 to 19.3 | 351 |
HPV | Up-to-Date, Females | States/Local Areas | New Jersey | 2020 | Age | 13-15 Years | 47.4 | 34.9 to 60.3 | 109 |
HPV | Up-to-Date, Females | States/Local Areas | New Jersey | 2019 | Age | 13-15 Years | 42.3 | 30.2 to 55.5 | 99 |
HPV | Up-to-Date, Females | States/Local Areas | New Jersey | 2018 | Age | 13-15 Years | 43.2 | 32.0 to 55.2 | 105 |
Varicella | History of disease | States/Local Areas | New Jersey | 2019 | Age | 13-17 Years | 6.9 | 4.1 to 11.3 | 331 |
Varicella | History of disease | States/Local Areas | New Jersey | 2017 | Age | 13-17 Years | 11.8 | 8.2 to 16.6 | 366 |
HPV | Up-to-Date, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Poverty | Living At or Above Poverty Level | 32 | 28.5 to 35.7 | 1,025 |
HPV | Up-to-Date, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Poverty | Below Poverty Level | 38 | 31.6 to 44.9 | 297 |
≥1 Dose MenACWY | null | States/Local Areas | Mississippi | 2018-2022 | Poverty | Living At or Above Poverty Level | 60.2 | 56.3 to 63.9 | 1,025 |
≥1 Dose MenACWY | null | States/Local Areas | Mississippi | 2018-2022 | Poverty | Below Poverty Level | 64.1 | 57.4 to 70.4 | 297 |
HPV | ≥1 Dose, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Poverty | Living At or Above Poverty Level | 52.5 | 48.7 to 56.3 | 1,025 |
HPV | ≥1 Dose, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Poverty | Below Poverty Level | 64.3 | 57.7 to 70.3 | 297 |
HPV | ≥1 Dose, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | White, Non-Hispanic | 44.1 | 40.0 to 48.4 | 822 |
HPV | ≥1 Dose, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Black, Non-Hispanic | 64.1 | 58.4 to 69.5 | 376 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Other or Multiple Races, Non-Hispanic | 91.1 | 81.8 to 95.9 | 98 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Hispanic | 95.9 | 90.1 to 98.4 | 76 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Black, Non-Hispanic | 90.1 | 85.7 to 93.3 | 376 |
≥1 Dose MenACWY | null | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Hispanic | 73.5 | 59.1 to 84.1 | 76 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | White, Non-Hispanic | 88.9 | 86.0 to 91.2 | 822 |
≥1 Dose MenACWY | null | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | White, Non-Hispanic | 53.8 | 49.6 to 58.0 | 822 |
≥1 Dose MenACWY | null | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Black, Non-Hispanic | 65.1 | 59.3 to 70.5 | 376 |
≥2 Doses MMR | null | HHS Regions/National | Region 8 | 2014 | Age | 13-17 Years | 88.5 | 86.2 to 90.5 | 2,290 |
HPV | Up-to-Date, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Other or Multiple Races, Non-Hispanic | 38.4 | 27.3 to 50.9 | 98 |
HPV | Up-to-Date, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Hispanic | 47.3 | 32.4 to 62.7 | 76 |
HPV | Up-to-Date, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Black, Non-Hispanic | 37.3 | 31.9 to 43.1 | 376 |
HPV | ≥1 Dose, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Other or Multiple Races, Non-Hispanic | 61.7 | 49.4 to 72.7 | 98 |
≥1 Dose MenACWY | null | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Other or Multiple Races, Non-Hispanic | 72.9 | 61.4 to 82.0 | 98 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a MSA Principal City | 88.5 | 81.5 to 93.1 | 214 |
HPV | ≥1 Dose, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | Hispanic | 70.5 | 56.1 to 81.8 | 76 |
HPV | Up-to-Date, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Race and Ethnicity | White, Non-Hispanic | 27.7 | 24.1 to 31.7 | 822 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a MSA Non-Principal City | 91.5 | 87.8 to 94.2 | 496 |
≥1 Dose MenACWY | null | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a MSA Non-Principal City | 59.9 | 54.4 to 65.2 | 496 |
≥1 Dose MenACWY | null | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a MSA Principal City | 69.5 | 61.6 to 76.4 | 214 |
≥1 Dose MenACWY | null | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a Non-MSA | 57.8 | 53.0 to 62.4 | 662 |
HPV | Up-to-Date, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a MSA Principal City | 42.5 | 34.6 to 50.8 | 214 |
HPV | Up-to-Date, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a MSA Non-Principal City | 34.7 | 29.7 to 40.1 | 496 |
HPV | Up-to-Date, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a Non-MSA | 28.5 | 24.3 to 33.2 | 662 |
HPV | ≥1 Dose, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a MSA Principal City | 62.9 | 54.7 to 70.4 | 214 |
HPV | ≥1 Dose, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a MSA Non-Principal City | 54.7 | 49.2 to 60.1 | 496 |
HPV | ≥1 Dose, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a Non-MSA | 51.7 | 46.9 to 56.4 | 662 |
HPV | Up-to-Date, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Overall | Overall | 33.3 | 30.2 to 36.5 | 1,372 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | Mississippi | 2018-2022 | Urbanicity | Living In a Non-MSA | 89.1 | 85.7 to 91.8 | 662 |
HPV | ≥1 Dose, Males and Females | States/Local Areas | Mississippi | 2018-2022 | Overall | Overall | 54.8 | 51.5 to 58.0 | 1,372 |
Tetanus | ≥1 Dose Tdap | States/Local Areas | Mississippi | 2018-2022 | Overall | Overall | 89.9 | 87.6 to 91.7 | 1,372 |
≥1 Dose MenACWY | null | States/Local Areas | Mississippi | 2018-2022 | Overall | Overall | 60.6 | 57.4 to 63.8 | 1,372 |
Varicella | History of disease | States/Local Areas | Kentucky | 2012 | Age | 13-17 Years | 33.9 | 27.4 to 41.0 | 333 |
Varicella | History of disease | States/Local Areas | Kentucky | 2013 | Age | 13-17 Years | 28.2 | 22.4 to 34.9 | 291 |
Varicella | History of disease | States/Local Areas | Kentucky | 2010 | Age | 13-17 Years | 48 | 41.8 to 54.3 | 309 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.